New biosimilar AVT16 takes on entyvio for ulcerative colitis
Disease control
Terminated
This phase 3 trial compared AVT16, a proposed biosimilar, to the approved drug Entyvio (vedolizumab) in 301 adults with moderate to severe ulcerative colitis. Participants received IV infusions over nearly a year. The study aimed to see if AVT16 works as well and is as safe as En…
Phase: PHASE3 • Sponsor: Alvotech Swiss AG • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC